October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
August 27, 2012 - N30 Pharma Converts from LLC to C-Corp

October 14, 2013 - Next generation F508del CFTR correctors using a YFP based high throughput screening assay
October 14, 2013 - Intestinal Current Measurement to Assess Modulation of F508del-CFTR Function
October 14, 2013 - A Novel GSNOR Inhibitor with Potent Bronchodilatory Effects and CFTR Potentiation Activity
March 21, 2013 - S-nitrosoglutathione Reductase Inhibitors Modulate F508-del CFTR Protein Levels and Chloride Secretion In Vitro
March 20, 2013 - Small Molecule Inhibitors of GSNOR Possess Anti-Inflammatory and Bronchodilatory Actions in Mouse Models of Inflammatory Lung Disease and Modulate CFTR Function in F508del-CFTR Mice

N30 Science

N30 Pharma Science

N30 Pharma has successfully developed a broad portfolio of proprietary, potent, small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) which have been shown to preserve endogenous S-nitrosoglutathione (GSNO) and produce potent bronchodilatory and anti-inflammatory effects in experimental models.

N30 Pharma’s drug portfolio consists of highly specific, reversible, and potent compounds with low nanomolar IC50 values for GSNOR. Multiple chemotypes suitable for intravenous (IV), oral, and inhaled administration have undergone rigorous screening for selection as drug candidates. N6022 is the first small molecule inhibitor of GSNOR under clinical development.

GSNOR Model

January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement

Newsroom

Posters

N30 Science

N30 Pharma Science

N30 Science

Papers